MARKET

CBPO

CBPO

China Biologic
NASDAQ

Real-time Quotes | Nasdaq Last Sale

118.28
-0.24
-0.20%
After Hours: 118.28 0 0.00% 16:00 04/13 EDT
OPEN
118.52
PREV CLOSE
118.52
HIGH
118.60
LOW
117.61
VOLUME
93.26K
TURNOVER
--
52 WEEK HIGH
120.01
52 WEEK LOW
99.52
MARKET CAP
4.59B
P/E (TTM)
30.49
1D
5D
1M
3M
1Y
5Y
Combination Therapy Drug Market May See a Big Move : Major Giants Grifols, Baxalta, Octapharma, Kedrion
Apr 09, 2021 (Market Insight Reports) -- Combination Therapy Drug Market Comprehensive Study is an expert and top to bottom investigation on the momentum...
Market Insight Reports · 4d ago
Platelet Rich Plasma Market Size, Growth, Manufacturers Segments and Forecast 2025
Japan, Japan, Thu, 08 Apr 2021 08:19:40 / Comserve Inc. / -- The report analyze market size, share, growth, trends, segmentation, top key players,...
Comserve · 5d ago
Hyperimmune Serum Market to Witness Huge Growth by 2026 | Grifols, Biotest, Kamada, ADMA Biologics
Apr 08, 2021 (Market Insight Reports) -- Hyperimmune Serum Market Comprehensive Study is an expert and top to bottom investigation on the momentum condition...
Market Insight Reports · 5d ago
Coagulation Factor Concentrates Market 2021 is Booming by Leading key Players - Forecast 2026 | CSL (Australia), Grifols (Spain), Shire (Ireland), Octapharma (Switzerland)
Market Stats News · 04/06 20:30
Global Intravenous Immunoglobulins Market Size, Share, Value, and Competitive Landscape 2020
Apr 05, 2021 (Heraldkeepers) -- Projected and forecast revenue values are in constant U.S. dollars, unadjusted for inflation. Product values and regional...
Heraldkeepers · 04/05 10:52
Global Biologic Therapeutic Drugs Market (2021 to 2025) - Featuring Amgen, Baxter and China Biologic Products Among Others
Dublin, April 02, Apr 02, 2021 (GLOBE NEWSWIRE via COMTEX) -- Dublin, April 02, 2021 (GLOBE NEWSWIRE) -- The "Biologic Therapeutic Drugs: Technologies and...
GlobeNewswire · 04/02 08:54
By 2025 Plasma Fractionation market size will be expected to grow with CAGR of 6.5%
Mar 31, 2021 (Market Insight Reports) -- Selbyville, Delaware. Plasma Fractionation Market Trends covers the companies' data including Growth potential...
Market Insight Reports · 03/31 06:07
China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2020
China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced its financial results for the fourth quarter and fiscal year of 2020.
PR Newswire · 03/29 21:30
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CBPO. Analyze the recent business situations of China Biologic through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CBPO stock price target is 102.78 with a high estimate of 119.00 and a low estimate of 77.00.
EPS
Institutional Holdings
Institutions: 136
Institutional Holdings: 14.68M
% Owned: 37.84%
Shares Outstanding: 38.79M
TypeInstitutionsShares
Increased
30
2.16M
New
20
1.06M
Decreased
28
2.49M
Sold Out
18
622.70K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.86%
Pharmaceuticals & Medical Research
+0.68%
Key Executives
Chairman/Chief Executive Officer/Director
Joseph Chow
Chief Financial Officer
Ming Yang
Director
Hui Li
Director
Yue'e Zhang
Independent Director
Yungang Lu
Independent Director
Qi Ning
Independent Director
Sean Shao
Independent Director
Xiaosheng Shao
No Data
  • All
  • Financials
  • Insiders
More
About CBPO
China Biologic Products Holdings, Inc. is a biopharmaceutical company. The Company is principally engaged in the research, development, manufacturing and sales of human plasma-based biopharmaceutical products in China. It operates through the manufacture and sales of human plasma products segment. China Biologic has a product portfolio with over 20 various dosage forms of plasma products and other biopharmaceutical products across nine categories.The Company's products include human albumin, human immunoglobulin, immunoglobulin for intravenous injection (IVIG), human hepatitis B immunoglobulin, human rabies immunoglobulin, human tetanus immunoglobulin, placenta polypeptide, Factor VIII and human prothrombin complex concentrate (PCC).

Webull offers kinds of China Biologic Products Holdings Inc stock information, including NASDAQ:CBPO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CBPO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CBPO stock methods without spending real money on the virtual paper trading platform.